Diabetic Cardiomyopathy

Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options

Ashish Aneja, W. H Wilson Tang, Sameer Bansilal, Mario J. Garcia, Michael E. Farkouh

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of coronary artery disease and hypertension. Hyperglycemia seems to be central to the pathogenesis of diabetic cardiomyopathy and to trigger a series of maladaptive stimuli that result in myocardial fibrosis and collagen deposition. These processes are thought to be responsible for altered myocardial relaxation characteristics and manifest as diastolic dysfunction on imaging. Sophisticated imaging technologies also have permitted the detection of subtle systolic dysfunction in the diabetic myocardium. In the early stages, these changes appear reversible with tight metabolic control, but as the pathologic processes become organized, the changes are irreversible and contribute to an excess risk of heart failure among diabetic patients independently of common comorbidities, such as coronary artery disease and hypertension. Therapeutic agents specifically targeting processes that lead to these pathophysiologic changes are in the early stages of development. Although glycemic control and early administration of neurohormonal antagonists remain the cornerstones of therapeutic approaches, newer treatment targets are currently being explored.

Original languageEnglish (US)
Pages (from-to)748-757
Number of pages10
JournalAmerican Journal of Medicine
Volume121
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Diabetic Cardiomyopathies
Coronary Artery Disease
Hypertension
Pathologic Processes
Hyperglycemia
Comorbidity
Myocardium
Fibrosis
Collagen
Therapeutics
Heart Failure
Technology

Keywords

  • Diabetes Mellitus
  • Diastolic dysfunction
  • Heart Failure
  • Pathophysiology
  • Treatment

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Diabetic Cardiomyopathy : Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. / Aneja, Ashish; Tang, W. H Wilson; Bansilal, Sameer; Garcia, Mario J.; Farkouh, Michael E.

In: American Journal of Medicine, Vol. 121, No. 9, 09.2008, p. 748-757.

Research output: Contribution to journalArticle

Aneja, Ashish ; Tang, W. H Wilson ; Bansilal, Sameer ; Garcia, Mario J. ; Farkouh, Michael E. / Diabetic Cardiomyopathy : Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options. In: American Journal of Medicine. 2008 ; Vol. 121, No. 9. pp. 748-757.
@article{2ac0925ef0344007a1f8f5bfe9f4a471,
title = "Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options",
abstract = "Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of coronary artery disease and hypertension. Hyperglycemia seems to be central to the pathogenesis of diabetic cardiomyopathy and to trigger a series of maladaptive stimuli that result in myocardial fibrosis and collagen deposition. These processes are thought to be responsible for altered myocardial relaxation characteristics and manifest as diastolic dysfunction on imaging. Sophisticated imaging technologies also have permitted the detection of subtle systolic dysfunction in the diabetic myocardium. In the early stages, these changes appear reversible with tight metabolic control, but as the pathologic processes become organized, the changes are irreversible and contribute to an excess risk of heart failure among diabetic patients independently of common comorbidities, such as coronary artery disease and hypertension. Therapeutic agents specifically targeting processes that lead to these pathophysiologic changes are in the early stages of development. Although glycemic control and early administration of neurohormonal antagonists remain the cornerstones of therapeutic approaches, newer treatment targets are currently being explored.",
keywords = "Diabetes Mellitus, Diastolic dysfunction, Heart Failure, Pathophysiology, Treatment",
author = "Ashish Aneja and Tang, {W. H Wilson} and Sameer Bansilal and Garcia, {Mario J.} and Farkouh, {Michael E.}",
year = "2008",
month = "9",
doi = "10.1016/j.amjmed.2008.03.046",
language = "English (US)",
volume = "121",
pages = "748--757",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Diabetic Cardiomyopathy

T2 - Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options

AU - Aneja, Ashish

AU - Tang, W. H Wilson

AU - Bansilal, Sameer

AU - Garcia, Mario J.

AU - Farkouh, Michael E.

PY - 2008/9

Y1 - 2008/9

N2 - Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of coronary artery disease and hypertension. Hyperglycemia seems to be central to the pathogenesis of diabetic cardiomyopathy and to trigger a series of maladaptive stimuli that result in myocardial fibrosis and collagen deposition. These processes are thought to be responsible for altered myocardial relaxation characteristics and manifest as diastolic dysfunction on imaging. Sophisticated imaging technologies also have permitted the detection of subtle systolic dysfunction in the diabetic myocardium. In the early stages, these changes appear reversible with tight metabolic control, but as the pathologic processes become organized, the changes are irreversible and contribute to an excess risk of heart failure among diabetic patients independently of common comorbidities, such as coronary artery disease and hypertension. Therapeutic agents specifically targeting processes that lead to these pathophysiologic changes are in the early stages of development. Although glycemic control and early administration of neurohormonal antagonists remain the cornerstones of therapeutic approaches, newer treatment targets are currently being explored.

AB - Diabetic cardiomyopathy is the presence of myocardial dysfunction in the absence of coronary artery disease and hypertension. Hyperglycemia seems to be central to the pathogenesis of diabetic cardiomyopathy and to trigger a series of maladaptive stimuli that result in myocardial fibrosis and collagen deposition. These processes are thought to be responsible for altered myocardial relaxation characteristics and manifest as diastolic dysfunction on imaging. Sophisticated imaging technologies also have permitted the detection of subtle systolic dysfunction in the diabetic myocardium. In the early stages, these changes appear reversible with tight metabolic control, but as the pathologic processes become organized, the changes are irreversible and contribute to an excess risk of heart failure among diabetic patients independently of common comorbidities, such as coronary artery disease and hypertension. Therapeutic agents specifically targeting processes that lead to these pathophysiologic changes are in the early stages of development. Although glycemic control and early administration of neurohormonal antagonists remain the cornerstones of therapeutic approaches, newer treatment targets are currently being explored.

KW - Diabetes Mellitus

KW - Diastolic dysfunction

KW - Heart Failure

KW - Pathophysiology

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=49849089716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849089716&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2008.03.046

DO - 10.1016/j.amjmed.2008.03.046

M3 - Article

VL - 121

SP - 748

EP - 757

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 9

ER -